Loading provider…
Loading provider…
Medical Oncology Physician in Indianapolis, IN
NPI: 1154313260Primary Practice Location
INDIANA UNIVERSITY HEALTH
1701 N Senate Blvd, Indianapolis, IN
Primary Employer
IU Health
iuhealth.org
HQ Phone
Get MD Elsayed's Phone Numberphone_androidMobile
Get MD Elsayed's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIN State Medical License

American Board of Internal Medicine
Medical Oncology
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 146 | 355 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 53 | 160 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 50 | 54 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 48 | 121 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 48 | 119 |
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, OTHER: Laboratory Biomarker Analysis, BIOLOGICAL: Ipilimumab, OTHER: Quality-of-Life Assessment
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, OTHER: Laboratory Biomarker Analysis, DRUG: Palbociclib
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, BIOLOGICAL: Nivolumab, OTHER: Laboratory Biomarker Analysis, BIOLOGICAL: Ipilimumab, OTHER: Pharmacological Study, DRUG: Taselisib, BIOLOGICAL: Tremelimumab, BIOLOGICAL: Durvalumab, DRUG: Palbociclib, DRUG: Erlotinib Hydrochloride, DRUG: Talazoparib, DRUG: FGFR Inhibitor AZD4547, BIOLOGICAL: Rilotumumab